NEW YORK, Sept. 10, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: MarketVIEW: Rotavirus vaccines
http://www.reportlinker.com/p02238857/MarketVIEW-Rotavirus-vaccines.html
Rotavirus transmitted by the faecal oral route causes fever and vomiting followed by diarrhoea/dehydration in neonates and infants. Recovery is usually complete but in the developing world, the virus is responsible for 5% of all deaths among children below five yrs (453,000 deaths in 2008).
Improvements in water quality and sanitation do not adequately prevent the spread of rotavirus such that vaccination is the best way to prevent severe infection. In 2009, the WHO recommended that rotavirus vaccines be included in all national immunisation programs and considered a priority. Two rotavirus vaccines, Rotarix (GSK Biologicals) and Rotateq (Merck & Co) have been licensed since 2006 and are used in both Western and developing world countries. New rotavirus vaccines are in development which may address the limitations of Rotarix and Rotateq.
This MarketVIEW comprehensive commercial opportunity assessment detailing the current and potential market for Rotavirus vaccine(s) using a patient based value/volume forecast for major Western markets, BRIC-MIT and GAVI countries to 2030. The forecast gives revenues and volume shares per vaccine per region taken into account the launch of new products and roll out into GAVI countries. The analysis also provides an update on competitor R&D activity and includes a detailed update of country national immunisation program parameters to date. Contents – Summary presentation (MS PowerPoint based)
Authors Note
Executive summary
Commercial model: key outputs
Rotavirus vaccines: global forecast revenue ($m) to 2030
Rotavirus vaccines: global forecast volume (000s doses) to 2030
Rotavirus vaccines: volume (000s doses) by country and vaccine – Major Western to 2030
Rotavirus vaccines: revenue ($m) by country and vaccine – Major Western to 2030
Rotavirus vaccines: volume (000s doses) by country and vaccine – BRICMIT to 2030
Rotavirus vaccines: revenue ($m) by country and vaccine – BRICMIT to 2030
Rotavirus vaccines: volume (000s doses) by WHO region and vaccine – GAVI to 2030
Rotavirus vaccines: revenue ($m) by WHO region and vaccine – GAVI to 2030
Rotavirus vaccines: market share by country and region in 2020*
Rotavirus vaccines: market share (volume and value) by vaccine in 2020*
Rotavirus vaccines: volume and revenue breakdown of 'Other' vaccines to 2030
Rotavirus: disease background and epidemiology
Rotavirus: the pathogen
Rotavirus transmission
Rotavirus diarrhoea
Protective immunity against rotavirus infection
Rotavirus: prevalence and incidence worldwide
Mortality associated with rotavirus
The global burden of RV diarrhoeal disease
Countries with the highest burden of RV-related deaths
Rotavirus: at-risk groups
Age distribution of rotavirus infections in children aged
<5 years, 2000–2011, England and Wales >Prevention of RV disease
Rotavirus vaccines: the current products and markets
Rotarix (GSK)
RotaTeq (Merck & Co)
WHO guidelines on rotavirus vaccination
National immunisation programmes – USA, Canada, Australia
National immunisation programmes – 5EU
National immunisation programmes – BRIC and MINT countries
GAVI-supported RV vaccine introductions by WHO region: 26 countries
National RV vaccine introductions by WHO region: 59 countries.
Coverage of national vaccination programmes.
New rotavirus vaccines: overview of current R&D
The need for new rotavirus vaccines
Rotavirus vaccine: ideal target product profiles
Live rotavirus vaccines in development
Non-replicating rotavirus vaccines
Rotavirus vaccines: Modelling the current market
Modelling methodology: overview
New product launch assumptions
Model inputs – USA, Canada, Australia
Model inputs – 5EU
Model inputs – BRIC
Model inputs – MINT
Model inputs – GAVI countries
WHO regions (as used in GAVI models)
Bibliography
Disclaimer
About VacZine Analytics
PAGES: 65 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model(s) (MS Excel-based) – 1 model
Title sheet CHARTS - global CHARTS - major Western (5EU +3) CHARTS - BRICMIT CHARTS – GAVI MS by country or region MS by vaccine MS other Vol Val global Vol Val 5EU+3 Vol Val GAVI US Canada United Kingdom France Germany Italy Spain Australia Brazil Russia. India. China Mexico Indonesia. Turkey GAVI Africa GAVI AMR + EMR GAVI EUR+SEAR+WPR Birth cohorts Infant mortality Assumptions Backpage
WORKSHEETS: ~30
To order this report: MarketVIEW: Rotavirus vaccines
http://www.reportlinker.com/p02238857/MarketVIEW-Rotavirus-vaccines.html
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article